Anemia and red blood cell transfusion in neurocritical care.
BACKGROUND
Anemia is one of the most common medical complications to be encountered in critically ill patients. Based on the results of clinical trials, transfusion practices across the world have generally become more restrictive. However, because reduced oxygen delivery contributes to 'secondary' cerebral injury, anemia may not be as well tolerated among neurocritical care patients.


METHODS
The first portion of this paper is a narrative review of the physiologic implications of anemia, hemodilution, and transfusion in the setting of brain-injury and stroke. The second portion is a systematic review to identify studies assessing the association between anemia or the use of red blood cell transfusions and relevant clinical outcomes in various neurocritical care populations.


RESULTS
There have been no randomized controlled trials that have adequately assessed optimal transfusion thresholds specifically among brain-injured patients. The importance of ischemia and the implications of anemia are not necessarily the same for all neurocritical care conditions. Nevertheless, there exists an extensive body of experimental work, as well as human observational and physiologic studies, which have advanced knowledge in this area and provide some guidance to clinicians. Lower hemoglobin concentrations are consistently associated with worse physiologic parameters and clinical outcomes; however, this relationship may not be altered by more aggressive use of red blood cell transfusions.


CONCLUSIONS
Although hemoglobin concentrations as low as 7 g/dl are well tolerated in most critical care patients, such a severe degree of anemia could be harmful in brain-injured patients. Randomized controlled trials of different transfusion thresholds, specifically in neurocritical care settings, are required. The impact of the duration of blood storage on the neurologic implications of transfusion also requires further investigation.
Kramer
Andreas H
AH
Departments of Critical Care Medicine & Clinical Neurosciences, University of Calgary, Foothills Medical Center, Calgary, AB, Canada. andreas.kramer@albertahealthservices.ca
Zygun
David A
DA
D000740:Anemia / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D001802:Blood Substitutes / Q000627:therapeutic use; D001930:Brain Injuries / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D017707:Erythrocyte Transfusion / Q000009:adverse effects; D006801:Humans; D020300:Intracranial Hemorrhages / Q000628:therapy; D020521:Stroke / Q000628:therapy; D016896:Treatment Outcome
D001802:Blood Substitutes